Impact of sarcopenia on post-liver transplant morbidity and mortality in cirrhotic patients

Kumar, Vijosh V.; Kothakota, Sunil Raviraj; Nair, Ajith K.; Sasidharan, Madhu; Harish, K; Kanala, Jagadeswarareddy; Kumar, Chitresh

doi:10.1007/s12664-022-01262-3

Cited by 7 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 1 summarizes the characteristics of all the studies encompassed in this meta-analysis. Out of the 40 studies, 18 were conducted in Asian regions ( 14 , 22–24 , 26 , 29 , 33 , 35 , 37 , 38 , 40 , 44 , 45 , 48 , 50 , 53 , 55 , 59 ), and the remaining 22 studies were from non-Asian regions ( 13 , 25 , 27 , 28 , 30–32 , 34 , 36 , 39 , 41–43 , 46 , 47 , 49 , 51 , 52 , 54 , 56–58 ). Among these 40 studies, 37 were cohort studies, 2 were cross-sectional studies ( 43 , 57 ), and 1 was a case-control study ( 35 ).…”

Section: Resultsmentioning

confidence: 99%

Correlation between sarcopenia and cirrhosis: a meta-analysis

Cui,

Zhang,

Guo

et al. 2024

Front. Nutr.

View full text Add to dashboard Cite

BackgroundThe relationship between sarcopenia and cirrhosis is unclear. In this research, our aim is to evaluate the prevalence of sarcopenia among individuals with liver cirrhosis and its correlation with survival and mortality risks.MethodsWe conducted searches on PubMed, Web of Science, EMBASE, and Cochrane for English articles published up to July 10, 2023, and additionally manually searched the bibliography of relevant articles. We incorporated research on sarcopenia in patients with cirrhosis to examine the connection between sarcopenia and the likelihood of survival and mortality. Statistical analyses were carried out utilizing the Stata version 15.1 software. Depending on the heterogeneity of the results, we employed either fixed-effects models or random-effects models for data synthesis. To assess publication bias, we employed funnel plots and conducted Egger’s test.ResultsWe included 40 studies involving 8,945 patients with cirrhosis. The overall prevalence of cirrhosis was 41% (95% CI 34%–48%). Male patients and those with liver cirrhosis and hepatic encephalopathy had a higher prevalence of sarcopenia (44% for male patients and 48% for hepatic encephalopathy patients). Sarcopenia emerged as a risk factor for both survival (HR = 2.57, 95% CI 2.02–3.27, p < 0.001) and mortality (HR = 2.13, 95% CI 1.86–2.44, p < 0.001) in patients with cirrhosis. Subgroup analyses consistently yielded the same results for study sites, whether HCC patients were excluded from the cohort, whether patients were from the liver transplant cohort or had undergone tips surgery, the definition of sarcopenia (L3-SMI or other methods), and the diagnostic criteria used by patients. The presence of sarcopenia was also a significant risk factor for hepatic encephalopathy [HR = 2.27, 95% CI (1.76–2.94), p < 0.001].ConclusionThis systematic review and meta-analysis reveal that patients with cirrhosis have a prevalence of sarcopenia of 41% and is associated with survival rate and mortality rate. Therefore, we should attach importance to the screening of sarcopenia in patients with cirrhosis, early detection of susceptible populations, and appropriate measures to reduce the occurrence and adverse outcomes.Systematic review registration:https://www.crd.york.ac.uk/PROSPERO/#recordDetails.

show abstract

Section: Resultsmentioning

confidence: 99%

Correlation between sarcopenia and cirrhosis: a meta-analysis

Cui,

Zhang,

Guo

et al. 2024

Front. Nutr.

View full text Add to dashboard Cite

show abstract

“…Our results, although conflicting, allowed for a peculiar analysis not found in other studies. Two included studies [20,22] reported a complete taxonomy of isolated microorganisms in ICU surgical infected patients. Secondary analysis did not reveal any statistically significant differences regarding any augmented risk for Gram positive, Gram negative and fungal infections.…”

Section: Discussionmentioning

confidence: 99%

Clinical Effects of Postoperative Parenteral Glutamine-Dipeptide Supplementation in Surgical Intensive Care Unit 3 Patients: a Systematic Review and Meta-analysis

Barone,

Frontera,

Liouras

et al. 2023

Preprint

View full text Add to dashboard Cite

Background- Glutamine plays a vital role as an energy substrate the inflammatory response, prevention of organ injury and renal acid buffering. Parenteral glutamine supplementation could reduce in-hospital and ICU morbidity and mortality. Objective- Aim of this systematic review and meta-analysis is to investigate the effects of parenteral administration of GLN in adult surgical critically ill ICU patients. Study selection- Two-arm studies about adult surgical ICU patients undergoing postoperative glutamine-enriched parenteral nutrition (experimental cohorts) vs control ones. Endpoints- Primary endpoint was in-hospital outcome (mortality, length of stay, length of mechanical ventilation). Secondary endpoint was the evaluation of nosocomial infections. Results- According to PRISMA ® 2020 flow diagram, eight randomized controlled trials were included for a total of 603 patients. No significant differences about in-hospital and ICU mortality were found (p=0.16 and p=0.53, respectively). Parenteral glutamine-supplementation was associated with a reduction of hospitalization (p=0.02), without influencing nor ICU stay (p=0.35) neither postoperative mechanical ventilation (p=0.18). Finally, dipeptide administration did not reduce cumulative incidence of nosocomial infections (p=0.41); however, a protective role for postoperative pneumonia was reported (p=0.05). Conclusions- Excepting for a reduction in hospital stay and incidence of nosocomial pneumonia, glutamine-dipeptide parenteral supplementation does not add any benefit in surgical ICU patients.

show abstract

“…In a meta-analysis including 3.803 patients on waiting lists (WLs) or undergoing liver transplantation (LT), van Vugt et al [ 83 ] reported a sarcopenia prevalence ranging from 22% to 70% [ 83 ]. Sarcopenia has been associated with WL [ 83 , 127 , 128 ], post-LT mortality [ 83 , 129 , 130 , 131 , 132 ] and with post-LT complications [ 73 , 130 , 131 , 133 , 134 ]. Only a few studies found no association between sarcopenia and post-LT mortality [ 73 , 134 , 135 ].…”

Section: Sarcopeniamentioning

confidence: 99%

Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease

Musio

Perazza

Leoni

et al. 2023

IJMS

View full text Add to dashboard Cite

Chronic liver disease (CLD), including non-alcoholic fatty liver disease (NAFLD) and its advanced form, non-alcoholic steatohepatitis (NASH), affects a significant portion of the population worldwide. NAFLD is characterised by fat accumulation in the liver, while NASH is associated with inflammation and liver damage. Osteosarcopenia, which combines muscle and bone mass loss, is an emerging clinical problem in chronic liver disease that is often underappreciated. The reductions in muscle and bone mass share several common pathophysiological pathways; insulin resistance and chronic systemic inflammation are the most crucial predisposing factors and are related to the presence and gravity of NAFLD and to the worsening of the outcome of liver disease. This article explores the relationship between osteosarcopenia and NAFLD/MAFLD, focusing on the diagnosis, prevention and treatment of this condition in patients with CLD.

show abstract

Impact of sarcopenia on post-liver transplant morbidity and mortality in cirrhotic patients

Cited by 7 publications

References 13 publications

Correlation between sarcopenia and cirrhosis: a meta-analysis

Correlation between sarcopenia and cirrhosis: a meta-analysis

Clinical Effects of Postoperative Parenteral Glutamine-Dipeptide Supplementation in Surgical Intensive Care Unit 3 Patients: a Systematic Review and Meta-analysis

Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease

Contact Info

Product

Resources

About